Lisa Trail
Nurse Practitioner · Murfreesboro, TNNPI 1174751671
Payments from drug & device makers
Across 492 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$904
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$764
- Takeda Pharmaceuticals U.S.A., Inc.$714
- Sanofi$384
- Regeneron Healthcare Solutions, Inc.$352
- plus $3K from 28 others
What the payments were for
- Food & beverage$8,38298%
- Education$2072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 157 | $2,502 |
| Johnson & Johnson | 48 | $904 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 60 | $764 |
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $714 |
| Sanofi | 13 | $384 |
| Regeneron Healthcare Solutions, Inc. | 19 | $352 |
| Gilead | 14 | $318 |
| Madrigal Pharmaceuticals | 9 | $292 |
| Braintree Laboratories, Inc. | 26 | $257 |
| Aimmune Therapeutics, Inc. | 16 | $257 |
| QOL Medical, LLC | 10 | $209 |
| Ardelyx, Inc. | 11 | $196 |
| Merck | 9 | $185 |
| Phathom Pharmaceuticals, Inc. | 9 | $147 |
| Pfizer | 5 | $104 |
| Lilly USA, LLC | 5 | $93 |
| Nestle Healthcare Nutrition Inc. | 5 | $88 |
| Organon | 3 | $85 |
| Ironwood Pharmaceuticals, Inc | 4 | $78 |
| Redhill Biopharma Inc. | 4 | $77 |
| Evoke Pharma, Inc. | 3 | $67 |
| Fresenius Kabi USA, LLC | 3 | $66 |
| Alcresta Therapeutics, Inc. | 1 | $64 |
| Daiichi Sankyo Inc. | 3 | $60 |
| Bristol Myers Squibb | 3 | $60 |
| Novo Nordisk | 3 | $60 |
| Vivus LLC | 3 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Intercept Pharmaceuticals, Inc. | 2 | $35 |
| Lucid Diagnostics Inc. | 1 | $23 |
| Medtronic | 1 | $22 |
| Celltrion USA Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Sandoz | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,590 in reported general payments places this provider in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RemicadeInfliximab | 22 | $172,993 |
| CreonLipase/Protease/Amylase | 31 | $118,803 |
| ZenpepLipase/Protease/Amylase | 15 | $76,176 |
| RelistorMethylnaltrexone Bromide | 18 | $67,330 |
| LinzessLinaclotide | 63 | $58,632 |
| IbsrelaTenapanor Hcl | 26 | $48,783 |
| XifaxanRifaximin | 12 | $38,216 |
| MotegrityPrucalopride Succinate | 18 | $15,262 |
| Mesalamine | 31 | $14,331 |
| TrulancePlecanatide | 22 | $12,292 |
| Lubiprostone | 14 | $3,063 |
| Pantoprazole Sodium | 199 | $2,556 |
| Famotidine | 161 | $2,030 |
| Budesonide DrBudesonide | 20 | $1,938 |
| Omeprazole | 112 | $944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $2,502 | $177,43594 claims |
| Johnson & JohnsonRemicade | $904 | $172,99322 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor, Xifaxan, Trulance | $764 | $117,83852 claims |
| Aimmune Therapeutics, Inc.Zenpep | $257 | $76,17615 claims |
| Ardelyx, Inc.Ibsrela | $196 | $48,78326 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $714 | $15,26218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Murfreesboro
- Amy HatcherMurfreesboro$1.1M
- Dana CarterMurfreesboro$31K
- Karen RodenKnoxville$265K
- Susan UtleyNashville$194K
- Whitney EricksonMemphis$159K
- Erica HembreeKnoxville$125K
- Brooke FaughtNashville$89K
- Lauren WelchNashville$71K
- Cara StoutKingsport$71K
- S Marie HamiltonOoltewah$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.